Latigo Biotherapeutics Inc.

NASDAQ: LTGO · Healthcare · Medical - Pharmaceuticals

PublicHQ Thousand Oak, CACIK 0002056611Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 41

v0.1 · 5/100 weight · pillars only

↑ market scale, listing tenure · ↓ listing tenure, market scale

Methodology →

Revenue TTM

—

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

—

Employees

—

as of 2026-08-08

Market cap

$1.1B

as of 2026-08-08

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

No filed financials — private or non-XBRL filer.

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Latigo Biotherapeutics Inc.’s financial profile?

Latigo Biotherapeutics Inc. has no structured financials on file — private or non-XBRL filer.

Peers · Healthcare

Vor Biopharma Inc.——Aktis Oncology, Inc.——Corvus Pharmaceuticals, Inc.——Seaport Therapeutics, Inc. Common Stock——Olema Pharmaceuticals, Inc.——Replimune Group, Inc.——

Key facts

CEONima Farzan

SectorHealthcare

IndustryMedical - Pharmaceuticals

HeadquartersThousand Oak, CA

ExchangeNASDAQ: LTGO

Employees—

IPO date2026-08-07

Latest filings

8-K2026-08-10

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.